Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Research

Circulating palmitoyl sphingomyelin levels predict the 10-year increased risk of cardiovascular disease death in Chinese adults: findings from the Da Qing Diabetes Study

Authors: Xin Qian, Hongmei Jia, Jinping Wang, Siyao He, Meng Yu, Xinxing Feng, Qiuhong Gong, Yali An, Xuan Wang, Na Shi, Hui Li, Zhongmei Zou, Guangwei Li, Yanyan Chen

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Higher levels of palmitoyl sphingomyelin (PSM, synonymous with sphingomyelin 16:0) are associated with an increased risk of cardiovascular disease (CVD) in people with diabetes. Whether circulating PSM levels can practically predict the long-term risk of CVD and all-cause death remains unclear. This study aimed to investigate whether circulating PSM is a real predictor of CVD death in Chinese adults with or without diabetes.

Methods

A total of 286 and 219 individuals with and without diabetes, respectively, from the original Da Qing Diabetes Study were enrolled. Blood samples collected in 2009 were used as a baseline to assess circulating PSM levels. The outcomes of CVD and all-cause death were followed up from 2009 to 2020, and 178 participants died, including 87 deaths due to CVD. Cox proportional hazards regression was used to estimate HRs and their 95% CIs for the outcomes.

Results

Fractional polynomial regression analysis showed a linear association between baseline circulating PSM concentration (log-2 transformed) and the risk of all-cause and CVD death (p < 0.001), but not non-CVD death (p > 0.05), in all participants after adjustment for confounders. When the participants were stratified by PSM-tertile, the highest tertile, regardless of diabetes, had a higher incidence of CVD death (41.5 vs. 14.7 and 22.2 vs. 2.9 per 1000 person-years in patients with and without diabetes, respectively, all log-rank p < 0.01). Individuals with diabetes in the highest tertile group had a higher risk of CVD death than those in the lowest tertile (HR = 2.73; 95%CI, 1.20–6.22).

Conclusions

Elevated PSM levels are significantly associated with a higher 10-year risk of CVD death, but not non-CVD death, in Chinese adults with diabetes. These findings suggest that PSM is a potentially useful long-term predictor of CVD death in individuals with diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference International Diabetes Federation. Diabetes and cardiovascular disease. Brussels, Belgium: International Diabetes Federation; 2016. www.idf.org/cvd. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels, Belgium: International Diabetes Federation; 2016. www.​idf.​org/​cvd.
15.
go back to reference Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985, 727:1–113. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985, 727:1–113.
17.
go back to reference Chen Y, Zhang P, Wang J, Gong Q, An Y, Qian X, Zhang B, Li H, Gregg EW, Bennett PH, Li G. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2021;64(6):1279–87. https://doi.org/10.1007/s00125-021-05401-x.CrossRefPubMed Chen Y, Zhang P, Wang J, Gong Q, An Y, Qian X, Zhang B, Li H, Gregg EW, Bennett PH, Li G. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2021;64(6):1279–87. https://​doi.​org/​10.​1007/​s00125-021-05401-x.CrossRefPubMed
Metadata
Title
Circulating palmitoyl sphingomyelin levels predict the 10-year increased risk of cardiovascular disease death in Chinese adults: findings from the Da Qing Diabetes Study
Authors
Xin Qian
Hongmei Jia
Jinping Wang
Siyao He
Meng Yu
Xinxing Feng
Qiuhong Gong
Yali An
Xuan Wang
Na Shi
Hui Li
Zhongmei Zou
Guangwei Li
Yanyan Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-02116-8

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.